153088-76-7

Usage

Uses

Used in Biochemical Research:
Z-ASP(OTBU)-BROMOMETHYLKETONE is used as a research tool for studying the mechanisms of aspartic proteases, particularly focusing on the role and function of cathepsin D in protein degradation. Its irreversible inhibition capability allows researchers to investigate the effects of enzyme inhibition on cellular processes and protein turnover.
Used in Drug Development:
In the pharmaceutical industry, Z-ASP(OTBU)-BROMOMETHYLKETONE is utilized in the development of drugs targeting aspartic proteases. Its specificity for cathepsin D makes it a valuable compound for designing therapeutic agents that can modulate the activity of this enzyme, potentially leading to treatments for diseases where abnormal protein degradation is implicated, such as certain types of cancer and neurodegenerative disorders.
Used in Pathophysiological Studies:
Z-ASP(OTBU)-BROMOMETHYLKETONE is employed in pathophysiological research to understand the role of cathepsin D in various disease conditions. By inhibiting the enzyme's activity, researchers can explore the consequences of altered protein degradation on cellular function and disease progression, providing insights into potential therapeutic targets and intervention strategies.

Upstream product

• 186581-53-3 diazomethane 
• 41446-22-4 (S)-3-Benzyloxycarbonylamino-4-isobutoxycarbonyloxy-4-oxo-butyric acid tert-butyl ester 
• 70-25-7 N-Methyl-N'-nitro-N-nitrosoguanidine 
• 5545-52-8 Z-D(tBu)-OH 
• 543-27-1 isobutyl chloroformate 
• 681447-89-2 2,6-bis-trifluoromethyl-benzoic acid 3-[2-(11-tert-butoxycarbonylamino-10-methyl-undecanoylamino)-3-phenyl-propionylamino]-2-oxo-propyl ester 
• 118248-02-5 Z-Asp(OBut)-CHN₂ 

Downstream Products

• 254751-09-2 (S)-tert-butyl 3-(((benzyloxy)carbonyl)amino)-4-oxo-5-(2,3,5,6-tetrafluoro phenoxy)pentanoate 
• 211918-92-2 2,6-dimethylbenzoic acid 3-benzyloxycarbonylamino-4-tert-butoxycarbonyl-2-oxo-butyl ester 
• 213613-50-4 C₂₅H₃₀N₂O₇ 

Relevant academic research and scientific papers

CASPASE INHIBITOR AND PHARMACEUTICAL COMPOSITION, USE AND THERAPEUTIC METHOD THEREOF

Disclosed are a class of compounds as a caspase inhibitor, and in particular the compound as shown in formula (I) or a pharmaceutically acceptable salt thereof, and the use of the compound in treating caspase-related diseases.

Caspase inhibitor and pharmaceutical composition, application and treatment method thereof

The invention provides a compound serving as a caspase inhibitor and particularly relates to a novel compound with caspase inhibition activity or a pharmaceutically acceptable salt of the novel compound, a preparation method of the novel compound and a ph

LINKED CYCLIC COMPOUND AS CASPASE INHIBITOR

A compound represented by formula (I), a pharmaceutically acceptable salt or tautomer thereof, and an application of the compound as a caspase inhibitor.

Structure-activity relationship study of a series of caspase inhibitors containing γ-amino acid moiety for treatment of cholestatic liver disease

A series of caspase inhibitors containing γ-amino acid moiety have been synthesized. A systemic study on their structure-activity relationship of anti-apoptotic cellular activity is presented. These efforts led to the discovery of compound 20o as a potent caspase inhibitor, which demonstrated preclinical ameliorating total bilirubin efficacy with a significantly improved pharmacokinetic profile.

Synthesis of N-urethane protected α-aminoalkyl-α-cyanomethyl ketones; Application to the synthesis of 3-substituted 5-amino-1H-pyrazole tethered peptidomimetics

The preparation of N-protected amino/peptide α-cyanomethyl ketones through cyanation of the corresponding α-bromomethyl ketones is described. The utility of the resulting α-cyanomethyl ketones in the synthesis of 3-substituted-5-amino-1H-pyrazoles has also been demonstrated. In both steps a wide range of N-protected amino/peptide acids has been employed and the products are obtained in good yield. The enantiomeric purity of both the α-cyanomethyl ketones and pyrazoles were confirmed by chiral HPLC analysis of the corresponding Z-protected d- and l-Ala-OH as model substrates. The synthesis of peptide pyrazolecarboxamides is also delineated. Georg Thieme Verlag Stuttgart · New York.

Synthesis and evaluation of indole aspartyl ketones as novel caspase-3 inhibitors

Synthesis, biological evaluation and structure-activity relationships for a series of novel nonpeptide small molecule inhibitors of caspase-3 are described. Among the synthesized compounds, 2,3,5,6-tetrafluorophenoxymethyl ketone derivatives of indole-N-a

CASPASE INHIBITORS BASED ON PYRIDAZINONE SCAFFOLD

The present invention relates to a pyridazinone derivative which can be used as a caspase inhibitor, process for the preparation thereof, and pharmaceutical composition for inhibiting caspase comprising the same.

CASPASE INHIBITORS BASED ON PYRIDAZINONE SCAFFOLD

The present invention relates to a pyridazinone derivative which can be used as a caspase inhibitor, process for the preparation thereof, and pharmaceutical composition for inhibiting caspase comprising the same.

CASPASE INHIBITORS BASED ON PYRIDAZINONE SCAFFOLD

The present invention relates to a pyridazinone derivative which can be used as a caspase inhibitor, process for the preparation thereof, and pharmaceutical composition for inhibiting caspase comprising the same.

CASPASE INHIBITORS CONTAINING DICARBONYLAMINO-ISOXAZOLINE

The present invention relates to a dicarbonylamino-isoxazoline derivative as an inhibitor against various caspases and a therapeutic composition for preventing inflammation and apoptosis comprising the same.